In addition to GLP-1, tirzepatide activates GIP receptors, potentially contributing to its effectiveness in weight loss. The exact role of GIP is uncertain, and it's unclear if it drives weight loss or improves GLP-1 activation.
Viking Pharmaceuticals is developing a drug that activates both GLP-1 and GIP receptors, showing promising weight loss results. Novo Nordisk, Eli Lilly, and Pfizer are also progressing in creating GLP-1 pills, aiming for easier administration and potentially lower costs.
Amgen's MariTide, targeting GLP-1 and GIP receptors, takes a unique approach by blocking GIP receptors instead of stimulating them. The mechanism behind weight loss effects from both stimulating and blocking these receptors remains unclear.
Collection
[
|
...
]